BioSpace News Archive

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and Chief Executive Officer and Michael Levitz, Executive Vice President, Chief Financial Officer and Treasurer, will present at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 3:45 p.m. ET.

Surgical Information Sciences (SIS), a medical device company focused on improved targeting for deep brain stimulation (DBS) surgery, announced it recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market an updated algorithm with new visualization capabilities.

Breast cancer survivors who are overweight have a statistically significant increased risk of developing second primary cancers, according to results from a study conducted by Kaiser Permanente researchers and published in the Journal of the National Cancer Institute.

Porzio Life Sciences, the leading provider of compliance solutions for the life sciences industry, today launched a market-leading solution that allows life sciences companies of all types to satisfy their spend transparency reporting obligations in the United States and 46 additional countries within a single platform.

Molecular Templates to Assume Full Rights to TAK-169, Second Generation ETB Targeting CD38 for the Treatment of Multiple Myeloma

Collaboration includes exclusive worldwide rights to Cidara’s CD388 and other influenza Antiviral Conjugates (AVCs) for up to $780 million in upfront, milestone payments and R&D funding

CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced its presence at the National Kidney Foundation’s 2021 Spring Clinical Meetings, which will take place virtually, April 6-10, 2021.

ION363, the first medicine to specifically target FUS-ALS, is among Ionis’ wholly owned assets the company plans to commercialize

Conference to include interim results from the open-label extension of the PULSAR Phase 2 trial showing consistent or improved responses in efficacy endpoints among sotatercept-treated patients

Affygility Solutions, an occupational health and safety consulting firm for the life sciences industry, announced its expansion into Brazil.